36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
The product is backed by required scientific proof and comparative bioequivalence studies
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
Post the sale, Patel family has become the single largest promoter shareholder in the company
The newly built centre will work as the state-of-the-art facility for not just ethical animal studies but spans from basic, applied to regulatory animal research.
Her previous role at Novartis, where she was general manager, data & digital, in global drug development, also included accountability for driving the DCT strategy, programs and platforms
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Subscribe To Our Newsletter & Stay Updated
